SK284521B6 - Použitie melatonínu na prípravu farmaceutického prostriedku - Google Patents

Použitie melatonínu na prípravu farmaceutického prostriedku Download PDF

Info

Publication number
SK284521B6
SK284521B6 SK1030-97A SK103097A SK284521B6 SK 284521 B6 SK284521 B6 SK 284521B6 SK 103097 A SK103097 A SK 103097A SK 284521 B6 SK284521 B6 SK 284521B6
Authority
SK
Slovakia
Prior art keywords
melatonin
benzodiazepine
treatment
sleep
patients
Prior art date
Application number
SK1030-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK103097A3 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of SK103097A3 publication Critical patent/SK103097A3/sk
Publication of SK284521B6 publication Critical patent/SK284521B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1030-97A 1995-02-01 1996-01-29 Použitie melatonínu na prípravu farmaceutického prostriedku SK284521B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (2)

Publication Number Publication Date
SK103097A3 SK103097A3 (en) 1998-01-14
SK284521B6 true SK284521B6 (sk) 2005-05-05

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1030-97A SK284521B6 (sk) 1995-02-01 1996-01-29 Použitie melatonínu na prípravu farmaceutického prostriedku

Country Status (22)

Country Link
JP (1) JP4516159B2 (lv)
CN (1) CN1083263C (lv)
AT (1) AT408188B (lv)
AU (1) AU695366B2 (lv)
BG (1) BG62876B1 (lv)
BR (1) BR9607169A (lv)
CZ (1) CZ291349B6 (lv)
DK (1) DK176081B1 (lv)
EE (1) EE03384B1 (lv)
FI (1) FI119586B (lv)
IS (1) IS1980B (lv)
LU (1) LU90118B1 (lv)
LV (1) LV11940B (lv)
MD (1) MD1716C2 (lv)
NO (1) NO312814B1 (lv)
NZ (1) NZ298878A (lv)
PL (1) PL183148B1 (lv)
SI (1) SI9620022A (lv)
SK (1) SK284521B6 (lv)
TR (1) TR199700723T1 (lv)
TW (1) TW483757B (lv)
WO (1) WO1996023496A1 (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227002B1 (en) 2000-01-05 2010-04-28 Neurim Pharma 1991 Use of melatonin in the manufacture of controlled release medicament for the prevention or treatment of symptoms of hypertension
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN109922795B (zh) * 2016-10-31 2021-10-08 纽里姆药物有限公司 褪黑素小片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
JPH10513177A (ja) 1998-12-15
SI9620022A (sl) 1998-10-31
CN1083263C (zh) 2002-04-24
ATA901396A (de) 2001-02-15
PL183148B1 (pl) 2002-05-31
DK176081B1 (da) 2006-04-18
CZ240597A3 (cs) 1998-01-14
SK103097A3 (en) 1998-01-14
JP4516159B2 (ja) 2010-08-04
AU695366B2 (en) 1998-08-13
MX9705856A (es) 1998-07-31
FI119586B (fi) 2009-01-15
NO312814B1 (no) 2002-07-08
EE9700166A (et) 1998-02-16
CN1172431A (zh) 1998-02-04
MD970254A (en) 1999-05-31
IS1980B (is) 2005-01-14
MD1716B2 (en) 2001-08-31
CZ291349B6 (cs) 2003-02-12
LV11940A (lv) 1998-01-20
BR9607169A (pt) 1997-11-11
BG101803A (en) 1998-04-30
AU4457496A (en) 1996-08-21
TR199700723T1 (xx) 1998-02-21
NO973531D0 (no) 1997-07-31
NZ298878A (en) 1999-05-28
EE03384B1 (et) 2001-04-16
PL321630A1 (en) 1997-12-08
FI973185A0 (fi) 1997-07-31
FI973185A (fi) 1997-09-30
TW483757B (en) 2002-04-21
MD1716C2 (ro) 2002-02-28
IS4532A (is) 1997-07-25
BG62876B1 (bg) 2000-10-31
LV11940B (lv) 1998-05-20
DK89697A (da) 1997-07-30
AT408188B (de) 2001-09-25
WO1996023496A1 (en) 1996-08-08
LU90118B1 (fr) 1997-11-13
NO973531L (no) 1997-09-30

Similar Documents

Publication Publication Date Title
Hajak et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study
Pallanti et al. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial
McElroy et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression
EP0724878B1 (en) Use of melatonin for treating patients suffering from drug dependencies
Csanalosi et al. Gepirone in anxiety: a pilot study
Cardinali et al. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly
Okos et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation
SK284521B6 (sk) Použitie melatonínu na prípravu farmaceutického prostriedku
US6835728B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
Neubauer Current and new thinking in the management of comorbid insomnia
US20080131532A1 (en) Fast asleep
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
US20080182904A1 (en) Baclofen for Relapse Protection in Addiction
Manfredi et al. Clinical neuropharmacology of sleep disorders
Modabbernia Melatonin and melatonin analogues for psychiatric disorders
Hajak et al. Clinical management of patients with insomnia: the role of zopiclone
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
Swieca et al. AUSTRALASIAN SLEEP ASSOCIATION POSITION STATEMENT AND GUIDELINES, REGARDING THE USE OF SODIUM OXYBATE IN THE TREATMENT OF NARCOLEPSY
EA035166B1 (ru) Фармацевтическая композиция, обладающая анксиолитическим и снотворным действием
Lee-Chiong et al. Pharmacologic Therapy of Chronic Insomnia in Older Adults
Prodhan et al. Melatonin and sleep disturbances in Alzheimer’s
Haino et al. Replacement Therapy in Older Patients with Sleep Disorders